MARKET

ALEC

ALEC

Alector
NASDAQ

Real-time Quotes | Nasdaq Last Sale

26.88
-0.53
-1.93%
Opening 13:41 02/27 EST
OPEN
27.20
PREV CLOSE
27.41
HIGH
27.89
LOW
26.22
VOLUME
446.37K
TURNOVER
--
52 WEEK HIGH
35.93
52 WEEK LOW
13.64
MARKET CAP
1.84B
P/E (TTM)
-17.8628
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of ALEC and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 5 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ALEC stock price target is 33.00 with a high estimate of 44.00 and a low estimate of 27.00.

EPS

ALEC News

More
  • Alector to Present at the Cowen 40th Annual Health Care Conference
  • GlobeNewswire · 3d ago
  • Stifel likes Alector and Denali in premarket analyst action
  • Seeking Alpha - Article · 02/19 12:06
  • Stifel Nicolaus Initiates Coverage On Alector with Buy Rating, Announces $44 Price Target
  • Benzinga · 02/19 10:51
  • IPO Update: Passage Bio Finalizes $126 Million IPO Plan
  • Seeking Alpha - Article · 02/18 20:57

Industry

Biotechnology & Medical Research
-1.79%
Pharmaceuticals & Medical Research
-1.03%

Hot Stocks

Symbol
Price
%Change
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%

About ALEC

Alector, Inc. is a clinical-stage biopharmaceutical company focused on immuno-neurology, a novel therapeutic approach for the treatment of neurodegeneration. Immuno-neurology targets immune dysfunction as a cause of multiple pathologies that are drivers of degenerative brain disorders. The Company is developing therapies designed to simultaneously counteract these pathologies by restoring healthy immune function to the brain. The Company's platform leverages large scale human genetic datasets, advanced tools in bioinformatics and imaging, and insights into neurodegeneration and immunology to identify immune system. Its platform focuses on target selection, biomarker selection and patient selection. Its product portfolio includes AL001, AL101, Al002 and AL003. Its AL001 targets frontotemporal dementia carrying a progranulin (FTD-GRN).
More

Webull offers kinds of Alector Inc stock information, including NASDAQ:ALEC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALEC stock news, and many more online research tools to help you make informed decisions.